Lenalidomide Market – By Type (5mg, 10mg, 15mg, 25mg Capsules), Application (Multiple Myeloma [MM], Myelodysplastic Syndromes [MDS]), End-user (Hospitals, Cancer Treatment Centers, Research Institutes) - Global Forecast, 2024 – 2032

Lenalidomide Market – By Type (5mg, 10mg, 15mg, 25mg Capsules), Application (Multiple Myeloma [MM], Myelodysplastic Syndromes [MDS]), End-user (Hospitals, Cancer Treatment Centers, Research Institutes) - Global Forecast, 2024 – 2032

Lenalidomide Market Size

Lenalidomide Market size was valued at USD 18 billion in 2023 and is anticipated to register a CAGR of 5.1% between 2024 and 2032. This surge is propelled by various factors, including the escalating prevalence of multiple myeloma worldwide and continuous advancements spurred by research endeavours.
 

Furthermore, the demand for lenalidomide remains vigorous, buoyed by its proven efficacy in managing multiple myeloma. A report from the American Association for Cancer Research and the National Cancer Institute's Epidemiology and End Results (SEER) program highlights that in 2022, 34,470 individuals in the U.S. were diagnosed with multiple myeloma, underscoring the increasing need for efficacious treatment options.
 

Lenalidomide is a medication classified as an immunomodulatory agent. It is primarily used in the treatment of certain types of cancer, particularly multiple myeloma, and myelodysplastic syndromes. Lenalidomide works by affecting the immune system and helping to slow down the growth of cancer cells.
 

Lenalidomide Market Trends

The landscape of blood cancer treatment is continually evolving, driven by advancements in innovative therapies. Lenalidomide plays a pivotal role, particularly as a complement to emerging treatments and in enhancing treatment efficacy.
 

• The market is propelled by the development of groundbreaking treatments for blood cancer. These advancements often emphasize combination therapies, where lenalidomide's role is to augment effectiveness or synergize with newer agents. As these novel treatments lead to improved patient outcomes and prolonged survival rates, the demand for lenalidomide surges, whether as a component of initial treatment strategies or subsequent lines of therapy.
   
• According to an article published by the Leukemia & Lymphoma Society in 2023, the recent FDA approvals of talquetamab-tgvs (Talve) and elranatamab (Elrexfio) for treating refractory or relapsed multiple myeloma mark a significant milestone in immunotherapy.
   
• These bispecific antibodies represent cutting-edge research-led advancements and are the first of their kind tailored specifically for multiple myeloma. The introduction of such novel treatment options underscores the dynamic evolution of multiple myeloma therapies.
   

Lenalidomide Market Analysis

Based on the type, the market is classified into 5mg capsules, 10mg capsules, 15mg capsules, and 25mg capsules. The 10mg capsules segment dominated the market with revenue of USD 6.1 billion in 2023.
 

• These capsules serve as a cornerstone in medical treatment regimens, offering patients a reliable and standardized dosage.
   
• The popularity of the 10mg capsule segment stems from its optimal balance between potency and controlled administration, rendering it a preferred choice among healthcare providers and patients alike. The versatility of the 10mg capsules ensures precise drug delivery, thereby contributing significantly to their widespread acceptance and dominance in the market.
   

Based on application, the lenalidomide market is classified into multiple myeloma (MM), myelodysplastic syndromes (MDS), and other applications. The multiple myeloma (MM) segment held the highest business share of 62.3% in 2023.

• Patients afflicted with multiple myeloma are expected to have a higher demand for lenalidomide and occupy a larger market. Lenalidomide is most commonly used to treat people with multiple myeloma. According to a study issued in the ASH Journal in May 2020, titled 'Prolonged lenalidomide maintenance therapy enhances the extent of response in multiple myeloma,' 34.3% of minimal residual disease positive patients with multiple myeloma at the initially resulted in negative after receiving lenalidomide treatment.
   
• The burgeoning market for lenalidomide has spurred major corporations to invest in its development to capitalize on its potential. For instance, in March 2022, MorphoSys, announced the temporary approval of tafasitamab for treatment of relapsed large B-cell lymphoma in combination with lenalidomide among adults. Thus, the increasing number of multiple myeloma diagnoses and treatments has resulted in higher use of the lenalidomide medication leading to a substantial impact to the market progress.
   

Based on end-user, the lenalidomide market is classified into hospitals, cancer treatment centers, research institutes. The hospitals segment is expected to hold the highest revenue throughout the forecast period.

• One of the key driving factors is its proven clinical efficacy in treating hematologic malignancies such as multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma. Clinical studies have consistently demonstrated the effectiveness of lenalidomide either as a monotherapy or in combination with other drugs, leading to improved patient outcomes such as increased progression-free survival and overall survival rates.
   
• Within hospital settings, there's a distinct emphasis on selecting medications backed by robust clinical evidence affirming their efficacy. The proven track record of lenalidomide profoundly shapes its uptake and utilization within hospitals, underlining its credibility as a trusted therapeutic option.
   

North America lenalidomide market accounted for USD 8.4 billion revenue in 2023 and is predicted to witness substantial market growth.
 

• North America exhibits a notably heightened incidence rate of these diseases in comparison to other regions globally. This elevated disease burden underscores the pressing need for potent treatments such as lenalidomide.
   
• Moreover, the presence of favorable reimbursement policies and stringent pharmaceutical regulations, particularly in countries like the U.S. and Canada, serves as a catalyst for the commercialization and adoption of lenalidomide. These conducive regulatory environments render the North American market particularly appealing to pharmaceutical companies, prompting heightened investments in marketing and distribution endeavors and consequently fueling market expansion.
   

Lenalidomide Market Share

The competitive landscape of the lenalidomide industry is characterized by the presence of established pharmaceutical companies vying for market share. Key players are engaging in strategic initiatives such as mergers, acquisitions, and partnerships to strengthen their product portfolios. The companies are actively adopting a multi-pronged approaches to address the rising demand for effective lenalidomide.
 

Lenalidomide Market Companies

Prominent players operating in the lenalidomide industry are as mentioned below

• Accord Healthcare
• Cipla
• Deva Pharma
• Dr. Reddy's Laboratories Ltd.
• Glenmark Pharmaceuticals
• Hetero
• Hikma Pharmaceuticals
• Lupin Limited
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Torrent Pharmaceuticals Ltd.
• Viatris Inc.
   

Lenalidomide Industry News

• In September 2022, Dr. Reddy’s Laboratories Ltd. introduced lenalidomide capsules, which are a generic counterpart to REVLIMID (lenalidomide) capsules, subsequent to receiving approval from the U.S. Food and Drug Administration (USFDA). This strategic initiative bestowed upon Dr. Reddy’s the distinction of being the first to market, along with a 180-day exclusivity period for the generic lenalidomide capsules, available in 2.5 mg and 20 mg potencies.
   
• In September 2022, Cipla Limited obtained the final endorsement from the U.S. FDA for its Abbreviated New Drug Application (ANDA) pertaining to lenalidomide capsules available in strengths of 5 mg, 10 mg, 15 mg, and 25 mg. These capsules are acknowledged as the AB-rated therapeutic equivalent generic variant of Bristol Myers Squibb's Revlimid (lenalidomide) Capsules.
   

The lenalidomide market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 - 2032 for the following segments

Click here to Buy Section of this Report

Market, By Type

• 5mg capsules
• 10mg capsules
• 15mg capsules
• 25mg capsules

Market, By Application

• Multiple myeloma (MM)
• Myelodysplastic syndromes (MDS)
• Other applications

Market, By End-user

• Hospitals
• Cancer treatment centers
• Research institutes

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • Rest of Middle East and Africa